AMKR insider filing: MaryFrances McCourt gains 51.0649 RSUs from dividends
Rhea-AI Filing Summary
MaryFrances McCourt, a director of Amkor Technology, Inc. (AMKR), reported accruals of dividend equivalent units that converted into additional restricted stock units on 09/23/2025. Two separate DEU accruals were recorded: 23.7001 RSUs related to a grant originally dated 05/16/2023, and 27.3648 RSUs related to a grant originally dated 05/15/2025. Each accrued unit represents an additional RSU subject to the same terms as its underlying award. Both acquisitions were recorded at a $0 price and increased the reporting person’s beneficial holdings to 8,862.7341 and 9,854.8917 shares respectively. The Form 4 was signed by an attorney-in-fact, Mark N. Rogers, on 09/25/2025.
Positive
- Director's equity alignment increased via accrual of 23.7001 and 27.3648 RSUs, reinforcing long-term alignment with shareholders
- No cash outlay required for the additional RSUs (recorded at $0), indicating the change arose from dividend equivalents rather than purchases
Negative
- None.
Insights
TL;DR: Routine dividend-equivalent accruals increased a director’s RSU holdings; no cash purchase or change in vesting terms disclosed.
The Form 4 documents standard dividend equivalent units credited to previously granted restricted stock units, increasing the director’s recorded beneficial ownership without any cash outlay. The accruals mirror ordinary compensation mechanics and do not indicate a new grant, sale, or other liquidity event. For governance oversight, this is a routine update confirming the director continues to receive equity-settled dividend equivalents consistent with existing awards.
TL;DR: DEUs converted to RSUs in modest amounts, increasing share-based compensation holdings; no exercise or cash transaction occurred.
The reported additions of 23.7001 and 27.3648 RSUs are attributable to dividend equivalents credited on 09/23/2025 and recorded at $0 price, consistent with standard equity compensation practices. These amounts are immaterial relative to typical executive equity grants but are relevant to total outstanding equity for the director. The filing does not disclose vesting schedule changes or accelerated vesting.